MDA 2023: Vyvgart of benefit across gMG duration, antibody status
Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) in patients regardless of their disease length, treatment history,…
Articles by Lindsey Shapiro, PhD
Sanofi is stopping clinical development of tolebrutinib for MG
Sanofi is stopping the clinical development of tolebrutinib for treating myasthenia gravis (MG), the company announced in a…
Phase 1 Trial of MuSK-CAART Therapy Is Recruiting
MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells…
Antibody Targeting IL-23 Eases MG Symptoms in Two Mouse Models
Treatment with an antibody targeting the interleukin-23 (IL-23) protein reduced symptoms and eased inflammation in mouse models of myasthenia…
Risk Factors For Myasthenic Crisis After Thymectomy Identified
Researchers have identified clinical factors that increase the risk of a post-operative myasthenic crisis (POMC) for patients with myasthenia gravis…
MuSK Protein’s Release Into Blood Could Underlie Autoimmunity in MG
Shedding of the muscle-specific tyrosine kinase (MuSK) protein from the surface of muscle cells into the bloodstream could be the…
Muscle Biopsy Could Help Secure MG Diagnosis for Unclear Cases
Analyzing the motor end-plate (MEP) — the specialized muscle region that communicates with a nerve cell — using a muscle…
NIH Grant Supports Work Into Faster, Simpler Test for MG Diagnosis
The National Institutes of Health (NIH) is supporting a pilot project that aims to develop a simple and fast diagnostic…
Metformin Seen to Target Immune Cells Driving MG in Early Research
Treatment with the diabetes medication metformin suppresses the growth of immune T- and B-cell subsets that are implicated in the…
Findings in UCB’s Myasthenia Gravis Pivotal Trials Detailed
Two investigational UCB treatments for generalized myasthenia gravis (gMG) — zilucoplan and rozanolixizumab — continue to show…